| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7829595 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(2 years from now) | |
| US9375405 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(2 years from now) | |
Sensipar is owned by Amgen.
Sensipar contains Cinacalcet Hydrochloride.
Sensipar has a total of 2 drug patents out of which 0 drug patents have expired.
Sensipar was authorised for market use on 08 March, 2004.
Sensipar is available in tablet;oral dosage forms.
Sensipar can be used as method of treating hyperparathyroidism; method of treating hypercalcemia.
The generics of Sensipar are possible to be released after 22 September, 2026.
Drugs and Companies using CINACALCET HYDROCHLORIDE ingredient
Market Authorisation Date: 08 March, 2004
Treatment: Method of treating hyperparathyroidism; Method of treating hypercalcemia
Dosage: TABLET;ORAL
SENSIPAR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic